C) Serum Multiplex Biomarker Profiling:

Fasting serum obtained from the patient twice, at age 13 years in 2010 and at age 14 years in 2011, was archived at −40°C until 2013 when studied by serum multiplex biomarker profiling (SMBP) of 22 analytes at Amgen, Inc. (Thousand Oaks, CA, USA). At both times, she was intermittently receiving alendronate. The studies used our published methodology^(20,21) in single “batch” assays to investigate many different rare metabolic and dysplastic bone disorders (Supplementary Appendix).⁽²⁰⁾ Results were contrasted to our SMBP values acquired in 2012 for fasting sera from 36 healthy children and adults (12 males and 24 females).^(20,21)